Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/dth.14785 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effective Mucosal Adjuvantation of the Intranasal Enterovirus A71 Vaccine With Zymosan.
Immunology
January 2025
Graduate Institute of Immunology, College of Medicine, National Taiwan University, Taipei, Taiwan.
Enterovirus A71 (EV-A71) has caused hand, foot, and mouth disease with an increased prevalence of neurological complications and acute mortality, threatening young children around the globe. By provoking mucosal immunity, intranasal vaccination has been suggested to prevent EV-A71 infection. However, antigens delivered via the nasal route usually fail to induce a protective memory response.
View Article and Find Full Text PDFThe effect of hand and foot exercises on peripheral neuropathy and quality of life in women with breast cancer: a randomized controlled trial.
Support Care Cancer
January 2025
Midwifery Department, Gülhane Faculty of Health Science, University of Health Sciences, Ankara, Turkey.
Purpose: Peripheral neuropathy is one of the most devastating symptoms experienced by the patients. Supportive and holistic care interventions are crucial to help these patients. The aim of this study is to determine the effects of hand and foot exercises on chemotherapy-induced peripheral neuropathy and quality of life in women with breast cancer.
View Article and Find Full Text PDFA data-driven model of disability progression in progressive multiple sclerosis.
Brain Commun
December 2024
Department of Health Sciences (DISSAL), Università di Genova, 16132 Genoa, Italy.
This study applies the Gaussian process progression model, a Bayesian data-driven disease progression model, to analyse the evolution of primary progressive multiple sclerosis. Utilizing data from 1521 primary progressive multiple sclerosis participants collected within the International Progressive Multiple Sclerosis Alliance Project, the analysis includes 18 581 longitudinal time-points (average follow-up time: 28.2 months) of disability assessments including the expanded disability status scale, symbol digit modalities, timed 25-foot-walk, 9-hole-peg test and of MRI metrics such as T1 and T2 lesion volume and normalized brain volume.
View Article and Find Full Text PDFEfficacy and safety of anlotinib combined with vinorelbine as second‑line treatment for elderly patients with advanced squamous cell lung carcinoma: A retrospective cohort.
Mol Clin Oncol
February 2025
Department of Thoracic Oncology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430079, P.R. China.
The aim of the present study was to investigate the efficacy and safety of anlotinib combined with vinorelbine (NVB) as a second-line treatment for elderly patients with advanced squamous cell lung carcinoma (SqCLC). The present retrospective analysis included 48 elderly patients (aged ≥65 years) diagnosed with advanced SqCLC who received anlotinib in combination with NVB as a second-line therapy between January 2021 and December 2023. The primary endpoints assessed were overall survival (OS), progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR) and safety profile.
View Article and Find Full Text PDFMaternal iron deficiency assessed by serum ferritin and birth outcomes in mainland China.
Sci Rep
January 2025
Centre for Public Health and Wellbeing, School of Health and Social Wellbeing, College of Health, Science and Society, University of the West of England, Bristol, UK.
Iron deficiency is prevalent among pregnant women because of the increased maternal iron requirements. Uncorrected maternal iron deficiency can lead to adverse neurodevelopmental outcomes in neonates. Therefore, the aim of this study was to assess serum ferritin concentration and prevalence of iron deficiency among pregnant women in Jiangsu, China.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!